Search | IOVS | ARVO Journals

Showing 1 – 20 of 32

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2022

Assessing Inhibition of HUVEC Migration by a Novel VEGF-A and Angiopoietin-2 Bispecific Protein (RO-634)

John Kunzeman; Jeffrey L Olson; Anthony Jones; Josh Morgenstern; Anne Strong; Steven Droho; Shaun Bevers; Niklaus Mueller; Michael Huvard; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Nikhil Gupta; Alina Sinha; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1325 – F0159. doi:

ARVO Annual Meeting Abstract June 2022

The Impact of Compartmental Exudative Volatility on Visual Acuity Outcomes in Neovascular AMD

Justis P Ehlers; Leina Lunasco; Sari Yordi; Hasan Cetin; Kubra Sarici; Thuy K Le; Katherine E Talcott; Robert Zahid; Joanne Hu; Xiangyi Meng; Peter K Kaiser; Arshad M. Khanani; Sunil K Srivastava

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):366 – F0197. doi:

ARVO Annual Meeting Abstract June 2022

Characterizing a Novel Bispecific Platform (Surrobody) for use in Back of the Eye Disease

Ramanath Bhandari; Li Xu; Evan Sembell; Jeffrey L Olson; Peter M Kaiser; Arshad M. Khanani; Jeffrey S Heier; Alina Sinha; John M Kunzeman; Nikhil Gupta; Ramesh Bhatt

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):302 – F0105. doi:

ARVO Annual Meeting Abstract June 2022

Suprachoroidal Delivery of RGX-314 Gene Therapy for Neovascular AMD: The Phase II AAVIATE™ Study

Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1497. doi:

ARVO Annual Meeting Abstract June 2022

Efficacy of the Treat-and-Extend Regimen in the Management of Neovascular Age-related Macular Degeneration: 8-year Results of the RENO Study

Rodney Dusit Fong; Mathew Thomas; Cecilia Romero; Jordyn Vannavong; Jonathan M Dang; Aamir Abdul Aziz; Phoebe Shappell; Adam Wadsworth; Fawwaz Siddiqui; Micaela Koci; Greggory M. Gahn; Nazrul Mojumder; Molly Hagen; Wei Yang; Jay Chhablani; Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1320 – F0154. doi:

ARVO Annual Meeting Abstract June 2022

Determining the Ocular Biocompatibility of a Novel VEGF-A and Ang-2 Bispecific Protein (RO-634) Through Histological Analysis

Evan Sembell; Jeffrey L Olson; Anthony Jones; Josh Morgenstern; Anne Strong; Steven Droho; Niklaus Mueller; Michael Huvard; Shaun Bevers; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Nikhil Gupta; John M Kunzeman; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):305 – F0108. doi:

ARVO Annual Meeting Abstract June 2022

Preclinical Animal Model for Functional Biocompatibility of a Novel VEGF and Ang-2 Bispecific Protein (RO-634) Using ERG Analysis

Nikhil Gupta; Jeffrey L Olson; Anthony Jones; Josh Morgenstern; Anne Strong; Steven Droho; Shaun Bevers; Niklaus Mueller; Michael Huvard; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Alina Sinha; Evan Sembell; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):286 – F0089. doi:

ARVO Annual Meeting Abstract June 2022

The Half Maximal Effective Concentration (EC50) of a Novel VEGF-A and Ang-2 Bispecific Protein (RO-634) for Back of the Eye Disease

Alina Sinha; Jeffrey L Olson; Anthony Jones; Josh Morgenstern; Anne Strong; Steven Droho; Shaun Bevers; Niklaus Mueller; Michael Huvard; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; John M Kunzeman; Evan Sembell; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1316 – F0150. doi:

Clinical Trials December 2021

Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema

PDF

Pravin U. Dugel; Arshad M. Khanani; Brian B. Berger; Sunil Patel; Mitchell Fineman; Glenn J. Jaffe; Petra Kozma-Wiebe; Jeffrey Heier
TAGS: diabetic macular edema, injections, plasma kallikrein, safety, inflammation, surrogate endpoints, eye
Trans. Vis. Sci. Tech.. 2021; 10(14):28. doi: https://doi.org/10.1167/tvst.10.14.28

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2021

Effectiveness of High Concentration (0.05%) Brilliant Blue G for ILM Staining during Macular Hole Surgery

Phoebe E Shappell; Taylor Orton; Jordyn Vannavong; Aamir A. Aziz; Fawwaz Siddiqui; Jay Chhablani; Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3664. doi:

ARVO Annual Meeting Abstract June 2021

Real World Efficacy and Safety of Brolucizumab in Neovascular AMD: The REBEL Study

Aamir Abdul Aziz; Arshad M. Khanani; Nikolas London; Molly M. Hagen; Carl J Danzig; Amol D Kulkarni; Veeral S Sheth; Chirag D Jhaveri; David Aaron Eichenbaum; Michael Singer

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):451. doi:

ARVO Annual Meeting Abstract June 2021

Efficacy of the Treat-and-Extend Regimen in the Management of Neovascular Age-Related Macular Degeneration: 7-Year Results of the RENO Study

Cecilia Romero; Jordyn Vannavong; Jonathan M. Dang; Aamir A. Aziz; Phoebe E Shappell; Adam Wadsworth; Fawwaz Siddiqui; Micaela Koci; Greggory M. Gahn; Nazrul Mojumder; Molly M. Hagen; Wei Yang; Jay Chhablani; Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):436. doi:

ARVO Annual Meeting Abstract June 2021

Faricimab in Neovascular Age-Related Macular Degeneration: 1-Year Efficacy, Safety, and Durability in the Phase 3 TENAYA and LUCERNE Trials

Arshad M. Khanani; Jeffrey Heier; Carlos Quezada Ruiz; Hugh Lin; David Silverman; Christopher Brittain; Jane Ives; Balakumar Swaminathan; Karen Basu; Tien Y Wong

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):428. doi:

ARVO Annual Meeting Abstract June 2021

Phase 1 Study of Intravitreal Gene Therapy with ADVM-022 for neovascular AMD (OPTIC Trial)

Brandon Busbee; David S Boyer; Arshad M. Khanani; Charles Clifton Wykoff; Dante Joseph Pieramici; Carl Regillo; Carl J Danzig; Brian C Joondeph; James Major; Carol Hoang; Adam Turpcu; Carol Chung; Szilard Kiss; Mehdi Gasmi; Aaron Osborne

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):352. doi:

ARVO Annual Meeting Abstract June 2020

High concentration (0.05%) Brilliant Blue G for staining during ERM peeling

Phoebe Shappell; Taylor Orton; Jordyn Vannavong; Aamir Aziz; Fawwaz Siddiqui; Jay Chhablani; Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1077. doi:

ARVO Annual Meeting Abstract June 2020

Phase 1 safety study of intravitreal (ITV) Anti-High Temperature Requirement A1 (aHtrA1), a novel serine protease inhibitor, in patients with Geographic Atrophy (GA)

Dante Joseph Pieramici; Arshad M. Khanani; Flavia Brunstein; Hao Chen; Ling Ma; Katie Maass; Irene Tom; Lee Honigberg; Eric C Strauss; Phillip Lai

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1942. doi:

ARVO Annual Meeting Abstract June 2020

A Novel Rapid Cooling Device for Intravitreal Injection Anesthesia: Results of the Prospective COOL-2 Study

Daniel L Chao; Charles Clifton Wykoff; Arshad M. Khanani; Gunho Kim

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4196. doi:

ARVO Annual Meeting Abstract June 2020

Efficacy of the Treat-and-Extend Regimen in the Management of Neovascular Age-related Macular Degeneration: 6-year Results of the RENO Study

Jordyn Vannavong; Jonathan Dang; Micaela M. Koci; Aamir Aziz; Fawwaz Siddiqui; Sylvia Phillips; Phoebe Shappell; Molly Hagen; Wei Yang; Jay Chhablani; Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4222. doi:

ARVO Annual Meeting Abstract June 2020

Phase 1 Study of Intravitreal Gene Therapy ADVM-022 for neovascular AMD (OPTIC Trial)

Arshad M. Khanani; Szilard Kiss; Adam Turpcu; Carol Hoang; Aaron Osborne

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1154. doi:

ARVO Annual Meeting Abstract July 2019

Checkup Mobile App to Monitor Visual Function in Diabetic Retinopathy and Age-related Macular Degeneration: The CLEAR Study

Arshad M. Khanani; Rahul N. Khurana; Lawrence J Singerman; Carol Hoang

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):1157. doi:

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Assessing Inhibition of HUVEC Migration by a Novel VEGF-A and Angiopoietin-2 Bispecific Protein (RO-634)

The Impact of Compartmental Exudative Volatility on Visual Acuity Outcomes in Neovascular AMD

Characterizing a Novel Bispecific Platform (Surrobody) for use in Back of the Eye Disease

Suprachoroidal Delivery of RGX-314 Gene Therapy for Neovascular AMD: The Phase II AAVIATE™ Study

Efficacy of the Treat-and-Extend Regimen in the Management of Neovascular Age-related Macular Degeneration: 8-year Results of the RENO Study

Determining the Ocular Biocompatibility of a Novel VEGF-A and Ang-2 Bispecific Protein (RO-634) Through Histological Analysis

Preclinical Animal Model for Functional Biocompatibility of a Novel VEGF and Ang-2 Bispecific Protein (RO-634) Using ERG Analysis

The Half Maximal Effective Concentration (EC50) of a Novel VEGF-A and Ang-2 Bispecific Protein (RO-634) for Back of the Eye Disease

Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema

Effectiveness of High Concentration (0.05%) Brilliant Blue G for ILM Staining during Macular Hole Surgery

Real World Efficacy and Safety of Brolucizumab in Neovascular AMD: The REBEL Study

Efficacy of the Treat-and-Extend Regimen in the Management of Neovascular Age-Related Macular Degeneration: 7-Year Results of the RENO Study

Faricimab in Neovascular Age-Related Macular Degeneration: 1-Year Efficacy, Safety, and Durability in the Phase 3 TENAYA and LUCERNE Trials

Phase 1 Study of Intravitreal Gene Therapy with ADVM-022 for neovascular AMD (OPTIC Trial)

High concentration (0.05%) Brilliant Blue G for staining during ERM peeling

Phase 1 safety study of intravitreal (ITV) Anti-High Temperature Requirement A1 (aHtrA1), a novel serine protease inhibitor, in patients with Geographic Atrophy (GA)

A Novel Rapid Cooling Device for Intravitreal Injection Anesthesia: Results of the Prospective COOL-2 Study

Efficacy of the Treat-and-Extend Regimen in the Management of Neovascular Age-related Macular Degeneration: 6-year Results of the RENO Study

Phase 1 Study of Intravitreal Gene Therapy ADVM-022 for neovascular AMD (OPTIC Trial)

Checkup Mobile App to Monitor Visual Function in Diabetic Retinopathy and Age-related Macular Degeneration: The CLEAR Study

To View More...

You must be signed into an individual account to use this feature.